The ambivalence of ERBB4 in PDAC, as in many other cancers, has emerged from studies assessing tumor‐suppressive functions for the receptor, in that ERBB4 expression was low in PDAC tissues and hPaCaCells (Kolb et al., 2007) and decreased in nonmetastatic tumors (Graber et al., 1999). Here, ERBB4 is linked to cancer.